AAMU
AXSM icon

Amundi Asset Management US’s Axsome Therapeutics AXSM Stock Holding History

Amundi Asset Management US’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$198K Sell
3,500
-100
-3% -$7.03K ﹤0.01% 1464
2020
Q4 		$293K Hold
3,600
– – ﹤0.01% 1377
2020
Q3 		$257K Buy
3,600
+1,800
+100% +$140K ﹤0.01% 1354
2020
Q2 		$148K Buy
+1,800
New +$139K ﹤0.01% 1412

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Amundi Asset Management US's AXSM Position: Q1 2021 in Review

Amundi Asset Management US reduced its Axsome Therapeutics (AXSM) stake by 2.8% in Q1 2021, selling an estimated $7.03K and leaving 3,500 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #1464.

Amundi Asset Management US first reported a position in AXSM in Q2 2020 and has held it in 4 quarters since. The position peaked at $293K in Q4 2020. 184 funds tracked by Wall St. Rank hold AXSM as of Q1 2021.

  • Amundi Asset Management US held 3,500 shares of Axsome Therapeutics worth $198K as of Q1 2021.
  • Amundi Asset Management US sold 100 Axsome Therapeutics shares in Q1 2021, an estimated $7.03K.
  • Axsome Therapeutics made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1464 holding.
  • Amundi Asset Management US first reported a position in Axsome Therapeutics in Q2 2020 and has held it in 4 quarters since.
  • Amundi Asset Management US's Axsome Therapeutics position peaked at $293K in Q4 2020.
  • 184 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.